(Q35129556)

6 August 2017

0 references

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis (English)

1 reference

6 August 2017

Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta‐analysis (English)

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Helicobacter pylori infectious disease

3 January 2024

main subject

Helicobacter pylori

0 references

1 reference

1 reference

2

X. Calvet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752350

3 January 2024

3

X. Calvet

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752350

3 January 2024

4

R. Azagra

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752350

3 January 2024

5

J. P. Gisbert

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752350

3 January 2024

author name string

Azagra R

3

1 reference

6 August 2017

Gisbert JP

4

1 reference

6 August 2017

E. Gené

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752350

3 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

6 August 2017

https://onlinelibrary.wiley.com/doi/pdfdirect/10.1046/j.1365-2036.2003.01566.x

file format

Portable Document Format

online access status

open access

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752350

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01566.x

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.2003.01566.x

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Alimentary Pharmacology & Therapeutics

3 January 2024

published in

1 reference

6 August 2017

volume

17

1 reference

6 August 2017

issue

9

1 reference

6 August 2017

page(s)

1137-1143

1 reference

Management of dyspepsia, gastroduodenal ulcer and Helicobacter pylori infection in primary care

6 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01566.X

The 1995 Albert Lasker Medical Research Award. Helicobacter pylori. The etiologic agent for peptic ulcer

21 January 2018

1

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

3 January 2024

2

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Prevention of ulcer recurrence after eradication of Helicobacter pylori: a prospective long-term follow-up study

3 January 2024

3

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study

3 January 2024

4

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

3 January 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Duodenal ulcer treated with Helicobacter pylori eradication: seven-year follow-up

3 January 2024

6

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer

3 January 2024

7

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report

3 January 2024

11

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Tratamiento erradicador de Helicobacter pylori. Recomendaciones de la Conferencia Española de Consenso

3 January 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Current concepts in the management of Helicobacter pylori infection--the Maastricht 2-2000 Consensus Report

3 January 2024

14

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Two-week dual vs. one-week triple therapy for cure of Helicobacter pylori infection in primary care: a multicentre, randomized trial

3 January 2024

16

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.

3 January 2024

18

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Factors influencing the eradication of Helicobacter pylori with triple therapy

3 January 2024

19

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases

3 January 2024

20

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Re-treatment after Helicobacter pylori eradication failure.

3 January 2024

21

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment.

3 January 2024

22

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori

3 January 2024

23

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Review article: one-week clarithromycin triple therapy regimens for eradication of Helicobacter pylori

3 January 2024

24

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

[Effectiveness of omeprazole, clarithromycin and amoxycillin therapy to eradicate Helicobacter pylori in patients with active peptic ulcer. Preliminary results of GENPY study]

3 January 2024

25

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection

3 January 2024

26

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

What is the optimal length of proton pump inhibitor-based triple therapies for H. pylori? A cost-effectiveness analysis

3 January 2024

27

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.

3 January 2024

28

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

[Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care]

3 January 2024

29

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

A method for assessing the quality of a randomized control trial

3 January 2024

32

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Three-day lansoprazole quadruple therapy for Helicobacter pylori-positive duodenal ulcers: a randomized controlled study

3 January 2024

34

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?

3 January 2024

36

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection

3 January 2024

37

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

A new quadruple therapy for Helicobacter pylori using tripotassium dicitrato bismuthate, furazolidone, josamycin and famotidine

3 January 2024

38

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Failure of a 1-day high-dose quadruple therapy for cure of Helicobacter pylori infection.

3 January 2024

39

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Preliminary study on a novel quadruple eradication therapy with a mucoprotective drug, sofalcone, for Helicobacter pylori infection

3 January 2024

40

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy

3 January 2024

41

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Impact of clarithromycin resistance on the effectiveness of a regimen for Helicobacter pylori: a prospective study of 1-week lansoprazole, amoxycillin and clarithromycin in active peptic ulcer

3 January 2024

42

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis

3 January 2024

43

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection

3 January 2024

44

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens

3 January 2024

48

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

'Rescue' therapy with rifabutin after multiple Helicobacter pylori treatment failures

3 January 2024

49

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

One-week omeprazole, furazolidone and amoxicillin rescue therapy after failure of Helicobacter pylori eradication with standard triple therapies

3 January 2024

50

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate

3 January 2024

51

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication

3 January 2024

52

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

Efficacy of two one-week rabeprazole/levofloxacin-based triple therapies for Helicobacter pylori infection

3 January 2024

53

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01566.X

3 January 2024

Identifiers

1 reference

release_bkw3cohigzaljlj5f4psheyvty

6 August 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/bkw3cohigzaljlj5f4psheyvty

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference